Antibody Ingredients TRIZ Cases

MASP-2 inhibitors selectively block lectin pathway initiation, reducing adverse effects while preserving classical immune function.

Modified human antibodies bind GPVI receptors with high affinity to block collagen-induced platelet aggregation.

A mutant human IgG4 antibody with a lysine at position 409 increases binding affinity to CD32b receptors.

Fc-optimized anti-CD47 antibodies enhance phagocytosis via targeted Fc mutations, resolving toxicity limits in malignancy treatment.

Humanized anti-PD-1 antibody blocks PD-1 receptor binding to enhance T cell cytokine production and overcome tumor-mediated immunosuppression.

A CAPRIN-1 specific antibody binds cancer cell surfaces to deliver targeted antitumor activity.

Anti-factor D monoclonal antibodies bind specifically to target proteins to inhibit the alternative complement pathway.

Segmenting immune checkpoint pathways with combined TIGIT, CD112R, and PD-1 blockade overcomes tumor evasion mechanisms that limit single-agent efficacy.

Cleavable linker releases cytotoxic payload inside cells to reduce systemic toxicity.

DS6-based diagnostic agent detects CA6 expression to stratify patients for antibody-drug conjugate therapy and reduce development attrition.

Anti-galectin-9 antibodies block signaling pathways to reduce metastasis and improve survival in uveal melanoma patients.

Combining PD-1, LAG3 antagonists, and lenvatinib improves clinical efficacy in non-MSI-H colorectal cancer patients.

An antibody targeting 3'-sialyl lactose enables precise antigen measurement.

Antibodies bind integrin alpha-v-beta-8, inhibiting TGF-beta activation to treat associated disorders.

Hu3F8V5 antibodies resolve stability and toxicity trade-offs by reducing immunogenicity while maintaining therapeutic efficacy.

Segmented IL10R binding molecules trigger intracellular signaling through selective receptor dimerization, eliminating off-target adverse effects.

Engineered antibodies specifically bind TREM-1 to prevent receptor dimerization and block ligand interaction.

Manipulating sugar concentrations in the culture medium controls TAF glycoform levels, resolving manufacturing precision versus medium complexity trade-offs.

Segmenting patients by LAG-3 expression enables precise PD-1 combination therapy selection, improving objective response rates.

Obinutuzumab treats nephrotic syndrome by depleting B-cells, resolving resistance and toxicity issues found with Rituximab.

Cross-linked antibodies neutralize Sema3A signaling to inhibit glioblastoma metastasis.

Bispecific antibodies recruit immune effectors to MAGE-expressing tumors, sparing healthy tissue.

Plant expression systems control antibody N-glycans to resolve mammalian cell heterogeneity and ensure consistent product quality.

Engineered antibodies with unpaired cysteine residues enable site-specific cytotoxin conjugation, reducing non-specific toxicity to healthy tissue.

FDF03 agonist antibodies bind inhibitory receptors to enhance antitumor immune responsiveness while mitigating autoimmunity risks.

Bispecific antibodies targeting GUCY2C and CD3 redirect T cells to kill tumors while sparing healthy tissue from systemic toxicity.

Replacing lambda light chains with kappa variants in the AFRA Fab fragment improves tumour localization while reducing radioactive toxicity in healthy tissues.

Modified Fc regions reduce side effects by inhibiting Treg functions while enhancing antitumor immunity.

Anti-progastrin antibodies target specific markers to overcome ineffective chemotherapy and improve survival rates.

Merges MetAP2 inhibition with VEGFR blockade to overcome limited efficacy and safety of existing renal cell carcinoma therapies.

An inhibitory anti-OX40 antibody blocks OX40/OX40L signaling to treat atopic dermatitis.

A salt-free pharmaceutical formulation maintains anti-EGFR antibody stability using sodium acetate and polysorbate 80.

Asymmetric bispecific darpins bridge CD123 tumor cells and CD3 T cells to reduce on-target off-tumor toxicity in acute myeloid leukemia.

A radiolabeled MCR1 ligand conjugate delivers radiation directly to metastatic melanoma cells.

Felzartamab depletes CD38-positive plasma cells through ADCC and ADCP, reducing circulating immune complexes in IgA nephropathy.

Jak3 inhibitors reduce inflammatory biomarkers and T cell infiltration, reversing hair loss despite unknown genetic causes.

Segmented ISV fragments inhibit HER3 signaling by blocking ligand binding, resolving kinase inactive receptor targeting challenges.

Afucosylated anti-CD20 antibodies enhance antibody-dependent cellular cytotoxicity while site-specific CD79b conjugation ensures reproducible therapeutic index.

Human monoclonal antibodies K1-18 and K1-70 bind to the thyroid-stimulating hormone receptor to modulate cyclic AMP activity.

Engineered anti-CD48 antibody drug conjugates deliver cytotoxic payloads to B lymphoblasts, resolving internalization and persistence bottlenecks.

Asymmetric IgM interfaces resolve manufacturing complexity while enhancing stability and production efficiency.

Anti-IL-20 antibody 7E reduces infarct areas by neutralizing IL-20, addressing inflammation and tissue damage in ischemic stroke.

Antibody drug conjugates bypass imatinib resistance by delivering cytotoxic agents directly to cKIT-expressing tumor cells.

A complete human anti-human TfR antibody targets cancer cells via phage display selection.

Engineered Fc regions tune antibody affinity to deplete regulatory T cells and enhance anti-tumor immunity without causing autoimmunity.

An anti-PfGARP antibody binds the EDKDGVEI epitope to induce programmed cell death in Plasmodium falciparum parasites.

Anti-CD3ε antibodies activate T cells via epsilon chain binding, reducing off-target effects with masking moieties.

Anti-CD123 antibodies deliver targeted radiation to leukemia cells while sparing normal tissues from off-target toxicity.